Medline Analyst Price Targets - Benzinga

Medline Inc

MDLNNASDAQ

Trade with Public

Trade with Public

$34.98

-0.09-0.26%

À la clôture: Sep 29, 5:00 PM EST

$35.14

0.160.46%

Après les heures: 4:12 PM EST

Aperçu Actualités Prévisions de résultats ÉvénementsObjectifs de coursDonnées financières Sentiment Actionnariat Comparer Options Rapport sur les stocks

Medline Analyst Price Targets

Wall Street analyst price targets and consensus rating for Medline (MDLN).

Price Target Range — 3 Quarters

Analyst Consensus — 23 Analysts

20Buy

3Hold

Consensus RatingOutperform# Analysts23Avg. Consensus PT$47Upside to Avg. PT+33.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 25, 2026	UBS	Kevin Caliendo	PT Cut	Buy	$45→$43
Aug 27, 2026	BTIG	David Larsen	Maintained	Buy	$55
Aug 12, 2026	JP Morgan	Lisa Gill	PT Cut	Overweight	$53→$46
Aug 11, 2026	Tigress Financial	Ivan Feinseth	PT Cut	Buy	$62→$55
Aug 11, 2026	Wells Fargo	Stephen Baxter	PT Cut	Equal-Weight	$45→$34
Aug 10, 2026	TD Cowen	Charles Rhyee	PT Cut	Buy	$53→$45
Aug 6, 2026	RBC Capital	Ryan Halsted	PT Cut	Outperform	$53→$46
Aug 6, 2026	Truist Securities	Jailendra Singh	PT Cut	Buy	$56→$47
Aug 6, 2026	Evercore ISI Group	Elizabeth Anderson	PT Cut	Outperform	$48→$39
Aug 6, 2026	Stifel	Rick Wise	PT Cut	Buy	$50→$45
Jul 31, 2026	BTIG	David Larsen	Maintained	Buy	$55
Jun 3, 2026	Baird	Eric Coldwell	PT Cut	Outperform	$57→$45
Jun 1, 2026	Barclays	Glen Santangelo	PT Cut	Overweight	$50→$45
May 14, 2026	BNP Paribas	Navann Ty	PT Cut	Neutral	$49→$40
May 13, 2026	Tigress Financial	Ivan Feinseth	PT Raise	Buy	$60→$62
May 7, 2026	Citigroup	Patrick Donnelly	PT Cut	Buy	$60→$55
May 7, 2026	Bernstein	Lee Hambright	PT Cut	Outperform	$56→$54
May 7, 2026	BTIG	David Larsen	Maintained	Buy	$55
Mar 11, 2026	Citigroup	Patrick Donnelly	Reinstates	Buy	$60
Mar 10, 2026	JP Morgan	Lisa Gill	PT Raise	Overweight	$50→$53

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
UBS Maintains Buy on Medline, Lowers Price Target to $43

UBS analyst Kevin Caliendo maintains Medline (NASDAQ:MDLN) with a Buy and lowers the price target from $45 to $43.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Medline, Maintains $55 Price Target

BTIG analyst David Larsen reiterates Medline (NASDAQ:MDLN) with a Buy and maintains $55 price target.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Medline, Lowers Price Target to $46

JP Morgan analyst Lisa Gill maintains Medline (NASDAQ:MDLN) with a Overweight and lowers the price target from $53 to $46.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Medline, Lowers Price Target to $34

Wells Fargo analyst Stephen Baxter maintains Medline (NASDAQ:MDLN) with a Equal-Weight and lowers the price target from $45 to $34.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Medline, Lowers Price Target to $45

TD Cowen analyst Charles Rhyee maintains Medline (NASDAQ:MDLN) with a Buy and lowers the price target from $53 to $45.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Medline, Lowers Price Target to $46

RBC Capital analyst Ryan Halsted maintains Medline (NASDAQ:MDLN) with a Outperform and lowers the price target from $53 to $46.

Benzinga Newsdesk